The new consortium partners expand CSDR's ability to help accelerate life-saving discoveries and efficiently translate big data into smart data that generates valuable research results.
With the addition of non-profit partners, CSDR is uniquely positioned to not only serve the research community through access to patient-level clinical data from the pharmaceutical industry, but also as a resource through which academic-led clinical trial data now can be shared.
ClinicalStudyDataRequest.com is an online resource giving researchers access to patient-level clinical trial data from 14 pharmaceutical companies across multiple therapeutic areas.
Its multi-sponsor request system provides a secure process for researchers to request access to global clinical trial data through a publicly available website.
An independent review panel reviews data requests received from external researchers. Wellcome Trust provides secretarial support to this panel and oversees the review process.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering